Chief Business Officer
Eidos Therapeutics is developing a novel treatment for transthyretin (TTR) amyloidosis (ATTR), a progressive, fatal disease affecting multiple organs including the heart and peripheral nerves. Current treatment options focus on managing the symptoms of the conditions, but do not address the underlying cause of the disease: TTR tetramers destabilized by mutations or age. Eidos’ lead compound, AG10, is a small molecule that binds and stabilizes TTR in the blood, preventing the formation of amyloid and potentially halting progression of the disease. Launched in 2016 after years of research supported by Stanford’s TRAM and SPARK programs, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to provide a safe, effective treatment for ATTR as quickly as possible.
The Controller will report directly to the CBO/CFO and is responsible for the accuracy and oversight of the general ledger accounting and payroll functions, the accounting and technical review for accounting of development expenses and clinical trials. The position requires an experienced leader and manager who demonstrates both analytical and in-depth technical skills on accounting principles and practices, accounting research, SEC reporting requirements and Sarbanes-Oxley requirements and the biotechnology and pharmaceutical industry.
· Manage private company accounting practices and while preparing the company to transition in to a publically traded company
· Review critical account reconciliations and continually improve the monthly and quarterly close processes.
· Identify and implement improvements to finance processes to streamline work and enhance controls.
· Work closely with the CBO/CFO on analysis and reports to support internal and external financial reporting.
· Prepare quarterly and annual financial statements ensuring compliance with GAAP and SEC reporting requirements.
· Assist in the preparation of Audit Committee Meeting Packages, including summary of actual results of operations.
· Prepare for and coordinate quarterly review, annual audit by auditors and necessary tax filings.
· Oversee 10-Q and 10-K (financial statements, footnotes, Selected Financial Data, Management’s Discussion, etc.).
· Manage a Sarbanes-Oxley compliance program including the development of financial reporting controls, maintenance of all required documentation, review of quarterly and annual control testing, and reporting quarterly and annual results to executive management, external auditors and the Audit Committee, as appropriate.
· Requires a strong financial background with a BS degree in business, accounting or finance. A CPA certification is preferred and Big Four public accounting experience highly desirable.
· Minimum of 10+ years of experience in an accounting/finance role working in fast growing companies with experience in taking a company public.
· Prior experience as a controller with responsibility for accounting and financial controls, or experience in auditing public companies and working with them on filings with the SEC.
· Demonstrated capability to manage complicated data consolidations and create timely, useful and accurate reports.
· A strong knowledge of the biotechnology or pharmaceutical industries.
· Strong financial systems knowledge and experience.
· Capabilities to develop financial business models to better analyze data.
· Strong interpersonal skills and communication skills to collaborate with all levels of an organization, strong organizational and multitasking capabilities, analytical and detail oriented flexibility in adapting to a fast-paced environment.